Nuclear Medicine and Biology
Volume 33, Issue 4 , Pages 513-520 , May 2006

Rhemium-186-monoaminemonoamidedithiol-conjugated bisphosphonate derivatives for bone pain palliation

  • Kazuma Ogawa

      Affiliations

    • Graduate School of Pharmaceutical Sciences, Kyoto University, Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan
    • Advanced Science Research Center, Kanazawa University, Kanazawa 920-8640, Japan
    • ,
  • Takahiro Mukai

      Affiliations

    • Graduate School of Pharmaceutical Sciences, Kyoto University, Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan
    • Graduate School of Pharmaceutical Sciences, Kyushu University, Higashi-ku, Fukuoka 812-8582, Japan
    • ,
  • Yasushi Arano

      Affiliations

    • Graduate School of Pharmaceutical Sciences, Chiba University, Chuo-ku, Chiba 260-8675, Japan
    • ,
  • Akira Otaka

      Affiliations

    • Graduate School of Pharmaceutical Sciences, Kyoto University, Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan
    • ,
  • Masashi Ueda

      Affiliations

    • Graduate School of Pharmaceutical Sciences, Kyoto University, Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan
    • ,
  • Tomoya Uehara

      Affiliations

    • Graduate School of Pharmaceutical Sciences, Chiba University, Chuo-ku, Chiba 260-8675, Japan
    • ,
  • Yasuhiro Magata

      Affiliations

    • Photon Medical Research Center, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan
    • ,
  • Kazuyuki Hashimoto

      Affiliations

    • Japan Atomic Energy Research Institute, Tokai-mura, Ibaraki 319-1195, Japan
    • ,
  • Hideo Saji

      Affiliations

    • Graduate School of Pharmaceutical Sciences, Kyoto University, Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan
    • Corresponding Author InformationCorresponding author. Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan. Tel.: +81 75 753 4556; fax: +81 75 753 4568.

Received 14 October 2005 ,Revised 17 March 2006 ,Accepted 17 March 2006.

References 

  1. Yoneda T, Sasaki A, Mundy GR. Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat. 1994;32:73–84
  2. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain. 1997;69:1–18
  3. Uppelschoten JM, Wanders SL, de Jong JM. Single-dose radiotherapy (6 Gy): palliation in painful bone metastases. Radiother Oncol. 1995;36:198–202
  4. Pandit-Taskar N, Batraki M, Divgi CR. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med. 2004;45:1358–1365
  5. McEwan AJ. Use of radionuclides for the palliation of bone metastases. Semin Radiat Oncol. 2000;10:103–114
  6. Elder RC, Yuan J, Helmer B, Pipes D, Deutsch K, Deutsch E. Studies of the structure and composition of rhenium-1,1-hydroxyethylidenediphosphonate (HEDP) analogues of the radiotherapeutic agent (186)ReHEDP. Inorg Chem. 1997;36:3055–3063
  7. Kolesnikov-Gauthier H, Carpentier P, Depreux P, Vennin P, Caty A, Sulman C. Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer. J Nucl Med. 2000;41:1689–1694
  8. Limouris GS, Shukla SK, Condi-Paphiti A, Gennatas C, Kouvaris I, Vitoratos N, et al. Palliative therapy using rhenium-186-HEDP in painful breast osseous metastases. Anticancer Res. 1997;17:1767–1772
  9. O'Sullivan JM, McCready VR, Flux G, Norman AR, Buffa FM, Chittenden S, et al. High activity rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone. Br J Cancer. 2002;86:1715–1720
  10. De Winter F, Brans B, Van De Wiele C, Dierckx RA. Visualization of the stomach on rhenium-186 HEDP imaging after therapy for metastasized prostate carcinoma. Clin Nucl Med. 1999;24:898–899
  11. de Klerk JM, van Dijk A, van het Schip AD, Zonnenberg BA, van Rijk PP. Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases. J Nucl Med. 1992;33:646–651
  12. Arano Y, Ono M, Wakisaka K, Uezono T, Akizawa H, Motonari Y, et al. Synthesis and biodistribution studies of 186Re complex of 1-hydroxyethylidene-1,1-diphosphonate for treatment of painful osseous metastases. Radioisotopes. 1995;44:514–522
  13. Ogawa K, Mukai T, Arano Y, Hanaoka H, Hashimoto K, Nishimura H, et al. Design of a radiopharmaceutical for the palliation of painful bone metastases: rhenium-186-labeled bisphosphonate derivative. J Label Cmpd Radiopharm. 2004;47:753–761
  14. Meyer JL, Nancollas GH. The influence of multidentate organic phosphonates on the crystal growth of hydroxyapatite. Calcif Tissue Res. 1973;13:295–303
  15. van Beek E, Hoekstra M, van de Ruit M, Lowik C, Papapoulos S. Structural requirements for bisphosphonate actions in vitro. J Bone Miner Res. 1994;9:1875–1882
  16. Kobayashi K, Motoishi S, Terunuma K, Rauf AA, Hashimoto K. Production of 186/188Re and recovery of tungsten from spent 188W/188Re generator. Radiochemistry. 2000;42:551–554
  17. Kieczykowski GR. New process for preparing an antihypercalcemic agent. UK Patent GB 2248061A, 1992.
  18. Kasugai S, Fujisawa R, Waki Y, Miyamoto K, Ohya K. Selective drug delivery system to bone: small peptide (Asp)6 conjugation. J Bone Miner Res. 2000;15:936–943
  19. Fujisawa R, Kuboki Y. Preferential adsorption of dentin and bone acidic proteins on the (100) face of hydroxyapatite crystals. Biochim Biophys Acta. 1991;1075:56–60
  20. van Aswegen A, Roodt A, Marais J, Botha JM, Naude H, Lotter MG, et al. Radiation dose estimates of 186Re-hydroxyethylidene diphosphonate for palliation of metastatic osseous lesions: an animal model study. Nucl Med Commun. 1997;18:582–588
  21. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998;19:80–100
  22. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest. 1996;97:2692–2696
  23. Jurisson SS, Benedict JJ, Elder RC, Whittle R, Deutsch E. Calcium affinity of coordinated diphosphonate ligands. Single-crystal structure of [(en)2Co(O2P(OH)CH2P(OH)O2]ClO4·H2O. Implications for the chemistry of technetium-99m-diphosphonate skeletal imaging agents. Inorg Chem. 1983;22:1332–1338
  24. Subramanian G, McAfee JG, Thomas FD, Feld TA, Zapf-Longo C, Palladino E. New diphosphonate compounds for skeletal imaging: comparison with methylene diphosphonate. Radiology. 1983;149:823–828
  25. Fogelman I, Pearson DW, Bessent RG, Tofe AJ, Francis MD. A comparison of skeletal uptakes of three diphosphonates by whole-body retention: concise communication. J Nucl Med. 1981;22:880–883
  26. Goeckeler WF, Edwards B, Volkert WA, Holmes RA, Simon J, Wilson D. Skeletal localization of samarium-153 chelates: potential therapeutic bone agents. J Nucl Med. 1987;28:495–504
  27. Ketring AR. 153Sm-EDTMP and 186Re-HEDP as bone therapeutic radiopharmaceuticals. Int J Rad Appl Instrum B. 1987;14:223–232

PII: S0969-8051(06)00062-X

doi: 10.1016/j.nucmedbio.2006.03.006

Nuclear Medicine and Biology
Volume 33, Issue 4 , Pages 513-520 , May 2006

Article Tools

* Image Usage & Resolution